We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Futura Medical Plc | LSE:FUM | London | Ordinary Share | GB0033278473 | ORD 0.2P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.30 | 0.77% | 39.10 | 39.00 | 39.90 | 40.00 | 39.10 | 39.60 | 157,664 | 12:49:07 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 0 | -5.85M | -0.0194 | -20.15 | 117.58M |
Date | Subject | Author | Discuss |
---|---|---|---|
25/4/2023 09:33 | For research purposes I decided to buy some. Large Boots in centre of Eastbourne Sold Out. Another local Boots Sold Out. Went to order online and was hoping for next day delivery but not an option. Seems to be selling well :) | pdt | |
25/4/2023 09:06 | ‘Rub on pain products – what you need to know’ ‘For many other rubbed-on products for pain relief (herbal remedies, salicylates, menthols, and some NSAID preparations) we have no evidence or so little evidence that we cannot trust it. It may work, but if you buy it, you have no idea whether you are buying something really good or just wasting your money. Experience suggests the latter, but if you have a remedy you swear by, stick with it. I know a chap who swears by rubbing WD40 on a sore back, but I wouldn’t recommend it’ | lbo | |
25/4/2023 08:48 | Does Voltaren work better then Flexiseq? Has a direct blind efficacy study been done? Does TPR100 work better then Flexiseq? We do know TPR100 gel (Dermasys plus Diclofenac) didn’t work better then Voltaren! ˜TPR100 gave similar results to the gold standard, Voltarol 2% gel’ | lbo | |
25/4/2023 08:33 | https://www.smsna.or | lbo | |
25/4/2023 08:33 | Cant I just take a tablet? ˜If you can get an erection in one situation and not the other, you do not need Viagra’ So via the non standard inclusion criteria in FM57. They only included men who already reported getting an erection with mechanical stimulation. So the men in FM57 could get an erection in one situation! So if the organic issue that Viagra counteracts is ruled out by the FM57 inclusion criteria then the men didn’t physiologically or biologically need to wait for viagra or any drug to work or to have a pharmacologic effect! They just need more arousal, or just a placebo! Or they need to be told the truth rather then be scammed into overpaying for a placebo arousal gel. Or they need to be offered CBT/psychotherapy to find out what is underlying the psychological issue. Also any placebo will work that the man believes will work! Including a cooling lubricant or arousal | lbo | |
25/4/2023 07:27 | Eroxon showing up on boots homepage!. | rv2 | |
25/4/2023 01:40 | Tried Voltarol, that doesn't work either. | glavey | |
24/4/2023 21:26 | Voltarol Emugel vehicle gel is made of the same ‘evaporative cooling’ ingredients as in Eroxon carbomer, isopropyl alcohol, propylene glycol, water Even ‘TPR100 (another Futura product but delivering Diclofenac) gave similar results to the gold standard, Voltarol 2% gel’ The cooling effect of a topically applied product can be evaluated using a validated handheld thermal imaging system. When the gel matrix is destroyed after application to the skin, the bound water and alcohol evaporates and a measurable cooling-effect results. Consumer satisfaction with a topical product is based on subjective criteria such as how the product feels and how it is perceived on the skin. Therefore, appropriate questionnaires are of major importance for cosmetic products to assess the subjective perception not only of soothing and cooling effects but also of moisturizing properties and fragrance. Skin hydration and cooling effect produced by the Voltaren® vehicle gel | lbo | |
24/4/2023 21:18 | Yeah long way to go to build it into a long term sustainable brand with regular repeat customers! Especially when theres still no enforceable patent so anyone can copy it based on the Voltaren vehicle ingredients being the same! Or as Futura openly admitted in the results. They will need to ˜work hard’ to try turn it ˜into a long term, profitable and trusted brand." 2013 Chemist shops sold out of new treatment three times since product came out in June flying off pharmacy shelves at the rate of 15,000 tubes a week The secured loan of US$15 million, which matures on June 25, 2018, will bear interest at 12% per annum plus other additional consideration. The interest rate will decrease to 10% if Pro Bono Bio meets certain equity-fundraising targets. The loan is secured by a charge over the assets of Pro Bono Bio and its affiliates which includes but is not limited to Flexiseq, an innovative topical pain product that has sales of more than 3 million units since its U.K. launch last year. In 2017, PBB was on the verge of bankruptcy, because it could not pay interest on the loan of 15 million pounds, taken in 2015 by the Canadian Knight Therapeutics. | lbo | |
24/4/2023 19:53 | Went into a branch of Boots with 10 packs on open display . Not in large plastic boxes as seen elsewhere . Small security tag stuck on back which I am sure could be removed with a blade . That will help our sales . Pleased to see someone else suggested not to list individual sales . | haroldthegreat | |
24/4/2023 18:35 | But is it ‘fair enough’ to claim a medical device is ‘clinically proven’ when the studies were not adequately placebo controlle? Doesn’t seem so according to the relevant ASA rulings! Medical device claims that breach CAP Code (Edition 12) rules 3.1 (Misleading advertising), 3.7 (Substantiation) and 12.1 Medicines, medical devices ‘Because the trial was not placebo-controlled&r ˜had not provided adequate evidence to support the claim ˜clinically proven’ ˜concluded that the claim had not been substantiated and was misleading’ Assessment Upheld The ASA noted that the product appeared to meet the requirements of the Medical Device Directive (MDD) but understood that the MDD did not harmonise EU law relating the advertising of medical devices, which was subject to Directive 2005/29/EC on unfair business to consumer commercial practices (including advertising) generally (Unfair commercial practices directive - UCPD). That meant that advertisers must still meet the requirements of the CAP Code, which reflected the provisions of UCPD. Under the CAP and BCAP Codes, medical claims could be made for CE-marked medical devices provided they complied with other requirements of the Codes, including those relating to substantiation. CE certification in itself does not constitute evidence for medical efficacy claims, and advertisers need to ensure that they hold evidence for such claims. There was no statistically significant difference between the outcomes for the treatment group (patients using the Aerosure device) and the control group (using an inactive sham device). The study was accordingly not adequate evidence of the efficacy Because the trial was not placebo-controlled, we considered AcceleDent had not provided adequate evidence to support the claim AcceleDent, is also clinically proven to reduce the pain and discomfort associated with braces and aligners by up to 71%. We concluded that the claim had not been substantiated and was misleading. On that point the claim breached CAP Code (Edition 12) rules 3.1 (Misleading advertising), 3.7 (Substantiation) and 12.1 Medicines, medical devices, health-related products and beauty products. Assessment Upheld The ASA noted that the product appeared to meet the requirements of the Medical Device Directive (MDD) but understood that the MDD did not harmonise EU law relating the advertising of medical devices, which was subject to Directive 2005/29/EC on unfair business to consumer commercial practices (including advertising) generally (Unfair commercial practices directive - UCPD). That meant that advertisers must still meet the requirements of the CAP Code, which reflected the provisions of UCPD. Under the CAP and BCAP Codes, medical claims could be made for CE-marked medical devices provided they complied with other requirements of the Codes, including those relating to substantiation. CE certification in itself does not constitute evidence for medical efficacy claims, and advertisers need to ensure that they hold evidence for such claims. There was no statistically significant difference between the outcomes for the treatment group (patients using the Aerosure device) and the control group (using an inactive sham device). The study was accordingly not adequate evidence of the efficacy | lbo | |
24/4/2023 18:33 | Fair enough dozey.Night folks :-) | broomrigg | |
24/4/2023 18:06 | Even sham acupuncture can be more effective then the placebo sham medical device Eroxon gel to stimulate ‘confidence&rs I wonder how many sham acupuncture devices could be sold in Boots claiming its ‘clinically proven’ to treat ED? The Efficacy of Acupuncture on Patients with Erectile Dysfunction: A Review All the studies showed that acupuncture had beneficial effects on ED, with effective rates from 54% to 69% Researchers have repeatedly shown interventions such as ˜sham’ acccupuncture to be as effective as acupuncture. Sham acupuncture uses retractable needles that do not pierce the skin | lbo | |
24/4/2023 17:13 | Just a couple of suggestions: first ignore LBO completely, it is a waste of time arguing logically with conspiracy theorists, they recognise neither logic nor truth and engaging with them is pointless; second don’t post trivia like individual sales, they are immaterial in the big picture. Let the board regain its usefulness PLEASE. | dozey3 | |
24/4/2023 17:02 | Page refreshed at 1801 hrsLast sale of Eroxon 33 seconds ago.Luverly jubberly ;-) | broomrigg | |
24/4/2023 16:56 | Early evening sales check at 1753 hrs.....Last sale of Eroxon via the boots.com website 7 seconds ago.Blimey, who dares wins Rodney!:-) | broomrigg |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions